Nemluvio

Asset

Monoclonal antibody targeting IL-31 receptor alpha to inhibit itching and inflammation.

Stage: Phase 3
Modality: Antibody
Target: Inflammation; 1
Indication: 0
Trials: 1
Developer

Indications

1

Atopic dermatitis
Phase 3, pmlive.com, 2 Oct 2026

In the full profile

Targets and what it contains2
Owner and partners1
Evidence for its targets1
Aging relevance1

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 7 Oct 2026, 1 source